Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-ALPRAZ | 0.25MG | TABLET | Resolved | 2018-07-04 | 2018-10-12 | 54165 |
| APO-ALPRAZ TS | 2MG | TABLET | Resolved | 2018-07-04 | 2020-09-28 | 54168 |
| APO-ALPRAZ TS | 2MG | TABLET | Resolved | 2017-06-07 | 2017-10-24 | 12241 |
| APO-AMBRISENTAN | 5MG | TABLET | Resolved | 2021-05-14 | 2021-06-14 | 139394 |
| APO-AMBRISENTAN | 10MG | TABLET | Resolved | 2021-05-14 | 2021-06-14 | 139397 |
| APO-AMIODARONE TABLETS | 200MG | TABLET | Resolved | 2018-05-15 | 2018-11-02 | 49418 |
| APO-AMIODARONE TABLETS | 200MG | TABLET | Resolved | 2024-05-24 | 2024-06-07 | 228816 |
| APO-AMIODARONE TABLETS | 200MG | TABLET | Resolved | 2023-09-15 | 2023-09-28 | 204408 |
| APO-AMIODARONE TABLETS | 200MG | TABLET | Resolved | 2023-03-23 | 2023-05-06 | 187727 |
| APO-AMIODARONE TABLETS | 200MG | TABLET | Resolved | 2020-10-07 | 2020-12-07 | 125800 |
| APO-AMITRIPTYLINE | 25MG | TABLET | Resolved | 2024-10-10 | 2025-01-11 | 239828 |
| APO-AMITRIPTYLINE | 50MG | TABLET | Resolved | 2021-06-04 | 2021-06-28 | 140414 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Resolved | 2021-06-25 | 2021-08-31 | 141518 |
| APO-AMITRIPTYLINE | 25MG | TABLET | Resolved | 2021-08-16 | 2022-05-13 | 144195 |
| APO-AMITRIPTYLINE | 50MG | TABLET | Resolved | 2021-10-08 | 2022-05-13 | 146901 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Resolved | 2021-10-22 | 2022-05-13 | 147809 |
| APO-AMITRIPTYLINE | 75MG | TABLET | Resolved | 2021-10-22 | 2022-06-17 | 147812 |
| APO-AMITRIPTYLINE | 10MG | TABLET | Resolved | 2023-10-20 | 2025-01-11 | 207698 |
| APO-AMLODIPINE | 10.0MG | TABLET | Resolved | 2018-03-05 | 2018-08-14 | 41847 |
| APO-AMLODIPINE | 5.0MG | TABLET | Resolved | 2018-03-13 | 2018-04-19 | 42669 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |